- 全部删除
您的购物车当前为空
LRRK2-IN-7 是一种具有选择性、CNS 渗透性和高效性的 LRRK2 激酶抑制剂(IC50:0.9 nM),可用于研究帕金森疾病。


为众多的药物研发团队赋能,
让新药发现更简单!
LRRK2-IN-7 是一种具有选择性、CNS 渗透性和高效性的 LRRK2 激酶抑制剂(IC50:0.9 nM),可用于研究帕金森疾病。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,980 | In stock | |
| 5 mg | ¥ 4,920 | In stock | |
| 10 mg | ¥ 7,130 | In stock | |
| 25 mg | ¥ 10,600 | In stock | |
| 50 mg | ¥ 13,800 | In stock |
LRRK2-IN-7 相关产品
| 产品描述 | LRRK2-IN-7 is a selective, CNS permeable and potent LRRK2 kinase inhibitor (IC50: 0.9 nM) for the study of Parkinson's disease. |
| 靶点活性 | LRRK2:0.9 nM |
| 分子量 | 414.5 |
| 分子式 | C24H26N6O |
| CAS No. | 2307277-93-4 |
| Smiles | C(#N)[C@@]1(C2(C1)CC2)C=3C=C4N(N=CC4=CC3)C=5C=C(N=CN5)N6C[C@H](C(C)(C)O)CC6 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 80 mg/mL (193.00 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.96 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容